Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or: Failed apnea reduction
Doxapram showed no clear difference in 1a. Failed apnea reduction after 2–7 days – doxapram compared to no… compared with no treatment, placebo, methylxanthine (including theophylline,… (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 1a. Failed apnea reduction after 2–7 days – doxapram compared to no treatment for the treatment of apnea · treatment of apnea Doxapram showed no clear difference in 1a. Failed apnea reduction after 2–7 days – doxapram compared to no… compared with no treatment, placebo, methylxanthine (including theophylline,… (low certainty). Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane Headline outcomes only | RR 0.45 [0.2, 1.05] | 1 study · 21 participants | Low |
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 1b. Failed apnea reduction after 2–7 days – doxapram compared to alternative treatment for the treatment of apnea · treatment of apnea It is very uncertain whether doxapram changes 1b. Failed apnea reduction after 2–7 days – doxapram compared to… compared with no treatment, placebo, methylxanthine (including theophylline,… (very low certainty). Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane Headline outcomes only | RR 1.35 [0.53, 3.45] | 4 studies · 84 participants | Very low |
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 1c. Failed apnea reduction after 2–7 days – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the treatment of apnea · treatment of apnea It is very uncertain whether doxapram changes 1c. Failed apnea reduction after 2–7 days – doxapram as an adjunct… compared with no treatment, placebo, methylxanthine (including theophylline,… (very low certainty). Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane Headline outcomes only | RR 0.08 [0.01, 1.17] | 1 study · 10 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Doxapram for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.